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THE KNEE PAIN MAP: THE RELIABILITY AND
REPRODUCIBILITYOF ASSESSING KNEE PAIN
LOCALIZATION AND PATTERNS IN PARTICIPANTS FROM
THE OSTEOARTHRITIS INITIATIVE
L. Raducha-Grace1, R. Boudreau1, M. Hannon1, A. Newman1,
M. Nevitt2, OAI Principal Investigators1, C. Kwoh1
1University of Pittsburgh, Pittsburgh, PA; 2University of
California, San Francisco, San Francisco, CA
Purpose: To describe the location and pattern of knee pain in
patients with chronic frequent knee pain using the Knee Pain
Map; and to evaluate the inter- and intra-rater reliability of the
Knee Pain Map.
Methods: The Knee Pain Map is an interviewer-administered as-
sessment that characterizes knee pain as localized (i.e., patellar,
superior-medial, inferior-medial, medial joint line, superior-lateral,
inferior-lateral, lateral joint line), regional (medial, lateral, patellar
or back of the knee) or diffuse (or unable to localize). Partic-
ipants are allowed to identify more than one location of pain.
Localized pain is deﬁned by the use of one or two ﬁngers to
point to a speciﬁc location, whereas regional pain is deﬁned by
the use of the all the ﬁngers or the whole hand to cover a more
extensive region. Participants in this study were from the Univer-
sity of Pittsburgh Osteoarthritis Initiative (OAI) Clinical Center, a
community based cohort of men and women, ages 49-75, with
symptomatic knee OA or with risk factors that increase their
risk of developing knee OA. Prevalence of knee pain by loca-
tion and pattern is described for a convenience sample of 869
participants who reported knee pain during the past 12 months.
Inter-rater reliability was assessed in 24 participants by two ob-
servers who independently recorded the locations of knee pain
of a single participant at the same session. Intra-rater reliability
was assessed in 88 participants by having the same observer
administer the Knee Pain Map in two separate sessions. Inter-
and intra-rater reliability were calculated in Stata using Fleiss’s
kappa. For the inter-rater reliability, each participant was rated
by two of seven different raters and the kappa calculation was
structured to account for non-unique raters.
Results: Participants most often reported localized pain (75%)
followed by regional (18%) or diffuse (8%) pain. In those with
localized knee pain, the most commonly reported zones were
the medial joint line (57%), lateral joint line (44%), and patella
(37%). Pain was less commonly reported in the inferior-medial
area (7%), superior-lateral area (7%), inferior lateral area (6%)
and the back of the knee (6%). In those with regional knee pain,
the most commonly reported regions were the patella (44%) and
medial region (44%), while the lateral region (27%) and the back
of the knee (22%) were less commonly reported. A small group
of patients (9%) reported diffuse pain or were unable to localize
their pain.
There was excellent inter-rater reliability for identiﬁcation of lo-
calized and regional pain patterns (kappa = 0.7-0.9 and 0.7-0.8,
respectively). The inter-rater reliability for speciﬁc localized zones
was also excellent (kappa = 0.7-1.0) when the number of partici-
pants with pain in that zone (n) was > 5. When n 5 and 0.68-1.0
when n<5. For regional pain, the speciﬁc regions varied from
0.68-1.0.
Abstract 62 – Table 1
OA deﬁnitions Hypermobility Non-Hypermobility Odds 95% CI
(% OA affected) (% OA affected) Ratio*
Hand: Modiﬁed ACR criteria 2.6% 15.4% 0.15 0.02–1.12
Hand: Gogo criteria 2.6% 17.8% 0.12 0.02–0.94
Hand: Any single joint involvement by examination 18.4% 42.9% 0.30 0.30–0.71
Knee: ACR criteria 11.1% 34.4% 0.24 0.67–0.85
*Odds of OA compoaring hypermobility to non-hypermobility group; Hand OA data available for n=287; Knee OA data available for n=120.
Conclusions: We have successfully demonstrated a system to
identify and record the localization and pattern of pain in knee
OA with excellent reliability. Knee pain was most often described
as localized, with the medial and lateral joint lines as the most
commonly reported zones. Only a small minority of patients
reported diffuse pain or were unable to localize their knee pain.
Additional studies are needed to determine if speciﬁc knee pain
patterns or locations correlate with known risk factors for knee
OA or with areas of pathologic changes seen on x-rays or MRIs
in patients with knee OA.
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ASSOCIATION OF OSTEOARTHRITIS, OSTEOARTHRITIS
BIOMARKERS AND ARTICULAR HYPERMOBILITY
H-C. Chen, T. Stabler, V.B. Kraus
Duke University Medical Center, Durham, NC
Purpose: To date, no studies have evaluated the association of
articular hypermobility and osteoarthritis (OA) biomarkers. The
ﬁrst aim of this investigation was to evaluate the relationship
between hypermobility and OA biomarkers in a large extended
family. Secondly, we assessed the odds of developing OA in
subjects with hypermobility and non-hypermobility.
Methods: The GIAFD family, standing for Gene-Environment
Interactions in Aging, Functional Decline and Disease family,
is one of the most extensively pedigreed existing families in
the United States comprising nine generations originating from
one founder born in the 1700s. Ascertainment of 365 members
was accomplished at three reunions between 2002, 2004 and
2006, and included blood sampling and complete medical history
(n = 350), physician-performed hand examinations for OA and
hypermobility (n=287), and knee examinations for OA (n=120).
We employed several deﬁnitions of hand OA including modi-
ﬁed American College of Rheumatology (ACR) criteria, GoGo
(Genetics of Generalized Osteoarthritis) criteria, and any single
hand joint (either DIP or PIP or CMC) involvement on examina-
tion. Knee OA was deﬁned by ACR criteria. Participants were
considered as exhibiting hypermobility if they scored 4 or more
points out of 9 according to the criteria established by Beighton in
1973. The sera in 278 participants were available and assessed
for six OA-related biomarkers: PIIANP (LINCO), CPII (IBEX), C2C
(IBEX), Cartilage Oligomeric Matrix Protein or COMP (inhouse
assay with monoclonal antibodies 17C10 and 16F12 provided by
Dr. V Vilim), HA (Corgenix), and hs-CRP (MAGIWEL). Biomarker
data were natural logarithm (Ln) transformed. The odds and 95%
conﬁdence intervals (CI) of hand or knee OA were determined for
the hypermobility group relative to the non-hypermobility group.
Unpaired t tests were used to assess the mean biomarker con-
centrations and mean numbers of hand joints involved in the
hypermobility and non-hypermobility groups. A P-value of <0.05
was considered statistically signiﬁcant.
Results: Hypermobility (Beighton score≥4) was present in 38
(13.2%) of the 287 examined participants. The hypermobility
group was on average, 4 years younger (51.7±15.6 years) than
the non-hypermobility group (56.1±15.1 years), but this was not
signiﬁcantly different (p=0.10). Of the 6 biomarkers assessed,
only Ln serum COMP was signiﬁcantly different and lower in the
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Abstract 62 – Table 2
Joint Site Hypermobility Non-Hypermobility p value/p value adjusted for age
mean # OA affected joints mean # OA affected joints
DIPs 0.21±0.62 0.60±1.35 0.08/0.22
PIPs 0.13±0.47 1.10±1.98 0.007/0.02
CMCs 0.026±0.16 0.15±0.49 0.13/0.26
DIPs+PIPs+CMCs 1.10±0.38 1.45±0.74 0.007/0.003
hypermobility group (7.26±0.46) vs. the non-hypermobility group
(7.42±0.64) (p=0.04). The ages of the 120 participants in the
knee examined subgroup were similar (hypermobility 51.2±15.8
years, non-hypermobility 57.6±15.8 years, p=0.06). The hyper-
mobility group showed consistently lower odds of hand OA (Table
1). The hypermobility group also showed a lower odds of knee
OA. By logistic regression, hypermobility was associated with a
decreased likelihood ratio of knee OA (p=0.012); however, after
controlling for age, the strength of the association was borderline
signiﬁcant (p=0.05). The hypermobility group also demonstrated
signiﬁcantly fewer OA affected PIP joints by examination (Table
2).
Conclusions: This cross-sectional study agrees with our pre-
vious study in a separate cohort showing that hypermobility
protects against OA of the PIP joints. We observed a similar
trend for OA of the DIP joints. This study suggests that joint
hypermobility might serve as a quantitative trait for identifying a
protective gene for OA.
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SEARCH FOR POTENTIAL OA OUTCOME BIOMARKERS
- “MULTIMARKER APPROACH”
O. Nemirovskiy1, M-P. Hellio Le Graverand2, T. Sunyer1,
M. Abrams1, P. Aggarwal1, D. Duﬁeld1, M. Radabaugh1,
A. Berglund1, W. Mathews1
1Pﬁzer, Inc., St. Louis, MO; 2Pﬁzer, Inc., Ann Arbor, MO
Purpose: Identiﬁcation of a panel of biochemical markers to
serve as surrogate biomarkers for measuring early efﬁcacy of
DMOAD therapies in OA clinical trials.
Methods: Urine, serum, and plasma cross-sectional samples
were collected from healthy and OA human subjects with symp-
tomatic OA, n = 22, subjects with no symptoms but radiographic
signs of OA (ROA) in knee/hip joints (n = 30), or ROA in
hand/spine joints (n = 18), and in subjects with no symptoms
or radiographic signs of OA (n = 12)). The diagnosis of symp-
tomatic OA (SOA) was based on a combination of pain or
stiffness on most days of a month during the past year and
the presence of radiographic OA as deﬁned by Kellgren and
Lawrence grades (KLG) 2 and 3. Samples were analyzed for
the levels of cartilage, bone, and synovium matrix degradation
and synthesis markers as well as for markers of inﬂammation.
Collagen type I neoepitope (TINE), type II (TIINE), type III (TI-
IINE), aggrecan neoepitope (Agg), and osteopontin peptides
were measured in urine by in-house developed LC-MS/MS as-
says. In plasma, 3-nitrotyrosine (3-NT) and procollagen type II
N-terminal propeptides (NPII) were measured by in-house devel-
oped immunoafﬁnity LC-MS/MS and competitive ELISA assays,
respectively. Urinary C-terminal telopeptides of type II collagen
(CTX-II) and plasma procollagen type I (PINP) and type III N-
terminal propeptides (PIIINP) were measured by published Elisa
assays. Plasma levels of prostaglandin PGE2 and 15-HETE
were determined by LC-MS/MS methods. Individual marker data
was analysed using one-way ANOVA and Bonferroni’s multiple
comparison test. Both principal component analysis (PCA) and
partial least squares (PLS) algorithms were applied to the entire
set of data.
Results: The levels of CTX-II, TIINE, TIIINE, osteopontin, PII-
INP, PGE2, 15-HETE, and 3-NT levels were signiﬁcantly higher
in symptomatic OA patients as compared to other groups (p-
values < 0.05 - 0.001). In contrast, plasma levels of NPII and
urinary levels of Agg were signiﬁcantly lower in SOA patients
as compared other groups (p-value < 0.001 for NPII, and <
0.05 for Agg). PINP and TINE levels were similar in all groups
(p-value = 0.4). The ratio of CTX-II or TIINE to NPII enhanced
the differences between SOA patients and other groups. Levels
of Agg marker were higher in the ROA in knee/hip group as
compared to no ROA or SOA groups (p value < 0.05). Unguided
PCA analysis was able to differentiate SOA subjects from the
subjects with ROA in knee/hip, hand/spine, and no ROA. Five
markers including PIIINP, pPGE2, 15-HETE, TIINE, and NP2
contributed most to the separation. Application of PLS-DA model
allowed for the separation of ROA in knee/hip group from the
ROA in hand/spine and no ROA. The most important markers
contributing to this separation were Agg, TIINE, PIIINP, PGE2,
and 15-HETE.
Conclusions: Application of biomarkers reﬂecting joint matrix
protein degradation and synthesis as well as inﬂammation may
provide a means of distinguishing subjects with symptomatic OA
from subjects showing only radiographic OA in knee/hip.
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CARTILAGE LONGEVITY: A PROGNOSTIC OA
BIOMARKER COMBINING BIOCHEMICAL AND
MRI-BASED CARTILAGE MARKERS
E.B. Dam1, M. Loog2, C. Christiansen1, M.A. Karsdal1
1Nordic Bioscience, Herlev, Denmark; 2University of
Copenhagen, Copenhagen, Denmark
Purpose: The study population selection criteria are essential
for the study outcome - without a high risk of progression in the
population if left untreated, no treatment will have any chance of
demonstrating an effect. The fundamental differences between
biochemical and MRI-based biomarkers suggest that combina-
tions may be appropriate. The purpose of this study was to
evaluate whether an aggregate prognostic biomarker targeting
cartilage longevity provided better performance than the individ-
ual markers.
Methods:A randomized population of 159 subjects was prospec-
tively selected with age 56.2±15.8, 48% female, and BMI
26.3±4.2. Radiographs were acquired in a semi-ﬂexed load-
bearing position using the SynaFlex. MRI scans were acquired
on a 0.18T Esaote scanner (Turbo 3D T1: 40° FA, TR 50 ms, TE
16 ms, 0.7 x 0.7 x 0.8mm3, time 10 min). Radiographs and MRI
were acquired at baseline (BL) and at follow-up (FU) after 21
months. Fasting morning urine samples were collected (second
void) at BL. 288 left and right knees were used in the study at BL
(after 25 knees were used for training of computer-based meth-
ods) and 245 knees at FU. The Kellgren and Lawrence (KL) score
was evaluated from the radiographs in the medial tibio-femoral
compartment and cartilage volume, mean thickness, congruity
(a measure of the surface curvature), surface smoothness, and
homogeneity (the entropy of the cartilage intensity distribution)
were quantiﬁed by a fully automatic, computer-based framework
in the medial tibial (and femoral) compartments. Urinary levels
of collagen type II C-telopeptide fragments (uCTX-II) were mea-
